←
Lumen Bioscience138 posts
Lumen Bioscience avatar

Lumen Bioscience

@LumenBio

Clinical-stage biotech developing new products for highly prevalent issues and diseases using the unique strengths of a novel platform organism

◷ Joined April 2017▧ 49 Photos and videos
Lumen Bioscience avatar
Lumen Bioscience@LumenBio·Aug 25

Lumen was awarded up to $7M from the Dept. of War to advance LMN-1001 — an intranasal antiviral that activates the body's own immune defenses — into Phase 1 trials. No pathogen ID needed, built for outbreaks & biodefense. Trial begins this fall. tinyurl.com/4de8ev8j

Post attachment
Lumen Bioscience avatar
Lumen Bioscience@LumenBio·Jan 14

Biotech's future isn't about higher prices—it's about global scale and prevention. The industry's old playbook is broken. Two structural shifts are reshaping what comes next. New piece from our CEO Brian Finrow and Kevin Klowden in BioCentury: tinyurl.com/2um67p3m

Post attachmentPost attachmentPost attachment
Brian Finrow avatar
⟳ Lumen Bioscience retweeted
Brian Finrow@Finrow·Jan 14

New piece from me and @KevinKlowden in BioCentury today. “The future of biotech is preventive — and global”

Post attachment
Brian Finrow avatar
⟳ Lumen Bioscience retweeted
Brian Finrow@Finrow·27 Nov 2025

Sure, extraordinary claims demand, extraordinary evidence. Fair enough. That said, while this is pending confirmation in the now-running phase 3 study, but we are encouraged by these preliminary results below: contagionlive.com/view/inves…

Zach Brennan avatar
⟳ Lumen Bioscience retweeted
Zach Brennan@ZacharyBrennan·21 Nov 2025

This Seattle co. says it can take the price of making mAbs/antibody drugs from $100/g to less than $0.10/g by growing them in a type of edible algae — and the Pentagon and Gates Foundation are listening endpoints.news/pentagon-back…

Lumen Bioscience avatar
Lumen Bioscience@LumenBio·22 Oct 2025

Think slow drug development = safe? Wrong. Australia approves low-risk trials in weeks. COVID proved remote trials work. China's biotech now dominates 1/3 of pharma acquisitions—not better science, just faster regulation. Time to fix U.S. inefficiencies. statnews.com/2025/06/03/us-

0:31
Lumen Bioscience avatar
Lumen Bioscience@LumenBio·15 Oct 2025

Thrilled to welcome David Saunders, MD, MPH to our clinical development team! A distinguished U.S. Army Colonel & clinical trialist, his expertise in infectious disease research will be crucial as we advance LMN-201 and our oral biologics pipeline. lumen.bio/news/2025/10/08/lu…

Post attachment
Brian Finrow avatar
⟳ Lumen Bioscience retweeted
Brian Finrow@Finrow·26 Jun 2025

.@rossry doesn't ask easy questions—he asks the right ones. Honored to be an early guest on the new @DevAndResearch interview series, where we dug deep on what makes drug development tick.

We're back with @DevAndResearch, where I spoke with @Finrow on: • why we should grow more drugs in algae, and fewer in Chinese Hamster Ovary cells, • why "monoclonal antibodies" are particularly safe and effective as drugs—but incredibly expensive to manufacture, • and whether the fundamental problem of the biotech industry is that everyone just has too much money. Timestamps: 01:17 What makes a molecule a drug? 04:48 What’s so great about antibody drugs? 05:59 The humble Chinese Hamster Ovary cell 11:27 Introducing: Lumen Biosciences 12:40 Why spirulina? 19:14 Why isn't everyone doing this? 23:53 Going after gut infections 33:44 “Cocktails” of protein drugs 50:25 Other diseases of outside-of-body lumens 01:04:36 How to run a different breed of biotech 01:17:44 “Everyone just has too much money” 01:21:07 Extinction events in the biotech industry…and “little mammals scurrying around” 01:24:28 Speculations about the future (for Lumen and the world of direct-to-consumer drugs)

1:33:02
Brian Finrow avatar
⟳ Lumen Bioscience retweeted
Brian Finrow@Finrow·3 Jun 2025

Good or bad, when institutions are remade it's an opportunity for fresh new ideas to root. There's plenty of negative criticism out there—from all sides—but @innovationwonk and I jotted down some constructive ideas to throw into the mix—published here in @statnews

Post attachment